MarketPeel
Insider Trading Intelligence
KS

Kathleen D. Scott

SPRY
CHIEF FINANCIAL OFFICER · ARS PHARMACEUTICALS, INC. · CIK 0001794284
FILING MIX · LIFETIME67%/33%
BUYS
18
SELLS
9
TOTAL VALUE
$1.48M
COMPANIES
2
ACTIVE SINCE
Aug 2021
HOLDINGS NOW
240,000
AVG SELL PX
$14.77
TRADE KIND
SHOWING 27 / 27
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
5 backtested trades · 8 horizons · 5 pending
Forward-return performance of every backtestable P/S trade by Kathleen D. Scott, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d5+80.00%-0.74%+0.25%-0.99%-2.10%
14d5+80.00%-4.75%+0.56%-5.31%-13.23%
30d5+80.00%+0.44%+1.09%-0.65%-2.40%
60d5+60.00%-4.73%+4.75%-9.48%+1.52%
90d5+100.00%-10.47%+3.96%-14.43%-13.05%
180d5+100.00%-19.10%+5.98%-25.08%-29.11%
1y5(1 pending)+75.00%-27.64%+17.88%-45.52%-45.17%
2y5(4 pending)+100.00%+140.56%+55.98%+84.58%+84.58%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
SPRY · 240,000 shares · as of Jan 2, 2026
0206,833413,665620,498827,3302023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 18 buys / 9 sellsCOVERAGE · 20 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
DRMA
DERMATA THERAPEUTICS, INC.
SALE
11$1.19$130Jun 16, 2026Jun 16, 2026View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
240,000240,000Jan 2, 2026Jan 5, 2026View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
2,5002,500Jan 2, 2026Jan 6, 2026View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
12,500$15.00$187.5K10,042Aug 21, 2025Aug 22, 2025View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
12,500$1.50$18.8K22,542Aug 21, 2025Aug 22, 2025View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
12,500739,830Aug 21, 2025Aug 22, 2025View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
50,000$1.50$75.0K57,424May 20, 2025May 22, 2025View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
50,000752,330May 20, 2025May 22, 2025View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
50,000$14.10$705.2K7,424May 20, 2025May 22, 2025View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,0005,000Jan 13, 2025Jan 14, 2025View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
176,700176,700Jan 2, 2025Jan 3, 2025View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
12,500802,330Oct 16, 2024Oct 17, 2024View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
12,500$1.50$18.8K17,449Oct 16, 2024Oct 17, 2024View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
12,500$16.00$200.0K4,949Oct 16, 2024Oct 17, 2024View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
12,500$1.50$18.8K25,699Aug 20, 2024Aug 21, 2024View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
12,500814,830Aug 20, 2024Aug 21, 2024View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
12,500$16.00$200.0K13,199Aug 20, 2024Aug 21, 2024View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
10,00010,000Jan 4, 2024Jan 5, 2024View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
200,000200,000Jan 2, 2024Jan 4, 2024View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
50,00050,000Jan 3, 2023Jan 5, 2023View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASE
Chief Financial Officer
8,250$6.24$51.5K8,250Nov 29, 2022Dec 1, 2022View →
SPRY
ARS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
827,330827,330Nov 8, 2022Nov 10, 2022View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
11,35927,145Oct 6, 2022Oct 7, 2022View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
9,96015,786Jul 7, 2022Jul 8, 2022View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,8265,826Apr 7, 2022Apr 8, 2022View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,0005,000Jan 3, 2022Jan 5, 2022View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
10,00010,000Aug 17, 2021Aug 17, 2021View →
Other insiders · SPRY
Loading peer insiders…
About this filer
CIK 0001794284
ROLE
Chief Financial Officer
PRIMARY
SPRY
COMPANIES
2
ACTIVE SINCE
Aug 2021
MARKETPEEL · /INSIDER/0001794284DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback